Supply Chain

Nearly half of business leaders believe their supply chains will become simpler in the near future, according to a survey from The Economist Intelligence Unit.

Amgen on May 25 filed a lawsuit against the Food and Drug Administration after the agency denied the drugmaker a six-month exclusivity period for its secondary hyperparathyroidism treatment Sensipar, reports Life Sciences Intellectual Property.

The U.S. Court of Appeals for the Eighth Circuit on May 26 ruled Fairview Health Services — a Minneapolis-based integrated health system and medical device seller — did not violate federal robocall rules, reports Blomberg BNA.

Two drug industry executives predict President Donald Trump will roll out proposals to tackle high drug costs within the next few weeks to months, reports Bloomberg.

HHS's Office of Inspector General estimates Mylan may have overcharged Medicaid $1.27 billion for EpiPens over the last decade by improperly classifying the devices as generic products under CMS' rebate program, reports STAT.

A nationwide sodium bicarbonate shortage piqued the interest of readers last month.

When a patient requires a medication adjustment to better manage high blood pressure, switching to a fixed-dose combination therapy is the most cost effective option, according to a study published in the Journal of Managed Care & Specialty Pharmacy.

University of Pittsburgh (Pa.) developed a seed capital fund to encourage the development of medications, reports the Pittsburgh Post-Gazette.

The Food and Drug Administration on Tuesday approved four drugmakers' generic versions of Strattera — Eli Lilly's attention-deficit/hyperactivity disorder drug.

Despite some progress, the supply chain industry is still a very "white male profession," according to Lora Cecere, founder and CEO of the research firm Supply Chain Insights.